Twenty healthy young men had oxytocin dripped into a vein at up to twice the concentration their bodies ever produce on their own. Their blood sugar did not move. Neither did their insulin output, their gut hormones, or the chemical markers that track bone being built up and broken down.
That is the finding of a randomized, placebo-controlled trial ↗ published September 3 in Diabetes, Obesity and Metabolism by a group at the Center for Clinical Metabolic Research at Copenhagen University Hospital-Herlev and Gentofte. It is a clean negative result on a hormone that a decade of animal work and small human studies had cast as a quiet regulator of metabolism and the skeleton.
What oxytocin was supposed to do
Oxytocin ↗ is a nine-amino-acid peptide, the same "love hormone" the body releases during birth, breastfeeding, and social bonding. It works through a single docking site, the oxytocin receptor ↗. Beyond its reproductive and social roles, a research thread built over the past decade suggested it might also steady blood sugar by nudging the pancreas, and might help maintain bone by shifting the balance between the cells that build bone and the cells that dissolve it. Some of that came from rodents. Some came from small, uncontrolled human studies. None of it had been tested under tight experimental control in people.
The test
The Copenhagen team ran the controlled version. Twenty men, average age 25 and lean, came in on three separate days for a randomized, double-blind, placebo-controlled crossover. On each visit they got either a low-dose oxytocin infusion (0.1 units per minute), a higher dose (0.2 units per minute), or plain saline, while their blood sugar was raised in steps every half hour through a graded glucose drip. Nobody, patient or researcher, knew which was which until the code was broken.
The doses were not subtle. They pushed circulating oxytocin to peaks of 193 and 401 picograms per milliliter, well above anything the body reaches on its own. The prespecified main question was whether that changed C-peptide, a marker the pancreas releases in lockstep with insulin, across the glucose challenge.
It did not. The C-peptide response was the same on oxytocin and on saline. So were plasma glucose, glucagon, the two incretin hormones GIP and GLP-1 (the same GLP-1 that the blockbuster weight-loss drugs mimic), and both bone markers the team tracked: CTX, which rises when bone is broken down, and P1NP, which rises when bone is laid down. Triglycerides too. Every readout landed on top of placebo.
Why a null result here is worth reading
A negative trial is easy to ignore and often the more honest signal. The authors, who include Jens Juul Holst and Filip Knop of the University of Copenhagen, two of the incretin field's most-cited clinical scientists, built the study specifically to separate a real effect from the noise that small uncontrolled studies generate. Under those conditions, acutely raising oxytocin did nothing measurable to the hormones that run blood sugar or the markers that track bone remodeling.
The result does not bury the idea outright, and the paper is careful about that. This was an acute infusion in healthy, lean, young men, not chronic dosing, not the nasal-spray route some studies use, and not people with obesity or metabolic disease where any effect might be easier to see. What it does is set a bar. If oxytocin has a metabolic or skeletal job in humans, a short high-dose infusion under a controlled glucose load is not enough to reveal it. One of the authors is affiliated with Novo Nordisk, whose GLP-1 franchise is the reason the incretin hormones measured in this study are household names.
It also fits a pattern in oxytocin research. When our coverage looked at oxytocin and social trust ↗, the effect turned out to exist only in a subgroup that started out wary. The metabolic and bone claims, put to a controlled test, produced nothing at all. Oxytocin keeps arriving with a bigger reputation than a clean experiment can confirm.